News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

January 24, 2024

Lipidor completes SEK 1.7 million sale of animal segment patent

STOCKHOLM, Sweden, 24th January 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that one of the company's patents, previously out-licensed to Emollivet AB, has now been sold to the same party. The sale is aimed at strengthening Lipidor's short term cash position. Since its inception…

December 23, 2022

The Board of Lipidor resolves to summon an Extraordinary General Meeting for approval of the sale of subsidiary shares to major owners

STOCKHOLM, 23 December 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI), (“Lipidor” or the “Company”) today announces that the…

December 14, 2022

Lipidor secures bridge financing of at least SEK 5 million through loans and subsidiary share sales, and takes cost-saving measures including staff layoffs

STOCKHOLM, Sweden, 14th December 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI), (“Lipidor” or the “Company”) today announces that…

December 8, 2022

Lipidor presents Nomination Committee

STOCKHOLM, Sweden, 8 December 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today presents its Nomination Committee, which shall…

November 23, 2022

Lipidor AB (publ) publishes interim report for third quarter 2022

STOCKHOLM, Sweden, 23 November 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the…

November 15, 2022

Lipidor provides update following outcome of Phase III study of psoriasis candidate AKP02

STOCKHOLM, 15 November 2022 – On October 28, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced that the Phase III…

October 28, 2022

Lipidor announces results from the company’s clinical Phase III study of AKP02 for psoriasis

STOCKHOLM 28 October 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III study…

October 7, 2022

Emollivet reaches milestone of over 1,000 products sold and prepares for scaled-up production

GOTHENBURG, Sweden, 7th October 2022 – Earlier this year, Lipidor’s subsidiary Emollivet launched Emollivet COMBI – an antiseptic emollient spray for horses…

September 29, 2022

Lipidor updates on Phase III clinical study of psoriasis candidate AKP02

STOCKHOLM, Sweden, 29 September 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that it has updated the…

August 25, 2022

Lipidor appoints new CFO Charlotta Ekman

STOCKHOLM, Sweden, 25 August 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that Charlotta Ekman has been…

August 24, 2022

Lipidor AB (publ) publishes interim report for second quarter 2022

STOCKHOLM, Sweden, 24 August 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the…